Related references
Note: Only part of the references are listed.Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
Yanjing Song et al.
PROTEIN & CELL (2018)
Driving gene-engineered T cell immunotherapy of cancer
Laura A. Johnson et al.
CELL RESEARCH (2017)
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
Jae H. Park et al.
BLOOD (2016)
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
Marcela V. Maus et al.
CLINICAL CANCER RESEARCH (2016)
Prospects for gene-engineered T cell immunotherapy for solid cancers
Christopher A. Klebanoff et al.
NATURE MEDICINE (2016)
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
Gregory L. Beatty et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Molecular genetics and targeted therapeutics in biliary tract carcinoma
Eric I. Marks et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
HER2 expression status in diverse cancers: review of results from 37,992 patients
Min Yan et al.
CANCER AND METASTASIS REVIEWS (2015)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors
Hinrich Abken
IMMUNOTHERAPY (2015)
Biliary Tract Cancers: Understudied and Poorly Understood
Emily Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
Hanren Dai et al.
ONCOIMMUNOLOGY (2015)
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
Yao Wang et al.
CLINICAL IMMUNOLOGY (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
OPINION The biliary tree-a reservoir of multipotent stem cells
Vincenzo Cardinale et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor
Yozo Nakazawa et al.
MOLECULAR THERAPY (2011)
HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
Nabil Ahmed et al.
CLINICAL CANCER RESEARCH (2010)
Preclinical Assessment of Simultaneous Targeting of Epidermal Growth Factor Receptor (ERBB1) and ERBB2 as a Strategy for Cholangiocarcinoma Therapy
Zichen Zhang et al.
HEPATOLOGY (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
被撤回的出版物: Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-κB in pancreatic cancer (Retracted article. See vol. 78, pg. 5477, 2018)
YX Zhang et al.
CANCER RESEARCH (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
The EGF receptor family as targets for cancer therapy
J Mendelsohn et al.
ONCOGENE (2000)
Share Paper
